Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs State Street SPDR S&P Biotech ETF — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.82 (market cap $78.25B), while State Street SPDR S&P Biotech ETF trades at $147.2 (market cap $10.27B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 7.6× State Street SPDR S&P Biotech ETF's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.14% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| NGG | XBI | |
|---|---|---|
Market Cap | $78.25B | $10.27B |
Volume | 1,070,031 | 9,751,587 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $93.93 | $169.55 |
52-Week Low | $73.54 | $107.32 |
Enterprise Value | $136.28B | — |
Dividend Yield | 4.14% | — |
Typical Hold Time | — | 39 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
